# Tag: Drug Approvals

## [The Long & Winding Road to Weight Loss Drugs](/content/whitepaper/the-long-winding-road-to-weight-loss-drugs/index.html)

## [The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model](/content/publication/the-impact-of-untreated-non-valvular-atrial-fibrillation-on-short-term-clinical-and-economic-outcomes-in-the-us-medicare-population-the-improve-af-model/index.html)

Click here for the publication.

## [5 Steps To Prepare For A Third-Party Drug Price Evaluation](/content/articles/5-steps-to-prepare-for-a-third-party-drug-price-evaluation/index.html)

In this Life Science Leader article, Matt Sussman discusses important steps to take when preparing for a third party drug price evaluation. Sussman notes that determining fair and reasonable drug prices in the U.S. has long been a source of debate as the U.S. has lacked consistent, independent economic analysis to assess the value of […]

## [Pandemic Pricing: The Risks and Rewards of Fast-Tracking Value-Based Drug Evaluations](/content/articles/pandemic-pricing-the-risks-and-rewards-of-fast-tracking-value-based-drug-evaluations/index.html)

Matt Sussman, VP of Modeling & Strategy at Panalgo, discusses the risks and rewards of fast-tracking drug price evaluations in the COVID era in this Pharmacy Times article. He notes that ICER’s expedited evaluation of remdesivir raises some questions related to value-based pricing evaluations that shouldn’t be overlooked. Read the full article for Sussman’s view […]